CDCP1, a transmembrane noncatalytic receptor, the expression of which has been associated with a poor prognosis in certain epithelial cancers, was found to be expressed in highly aggressive triple-negative breast cancer (TNBC) cell models, in which it promoted aggressive activities-ie, migration, invasion, anchorage-independent tumor growth, and the formation of vascular-like structures in vitro. By immunohistochemical (IHC) analysis of 100 human TNBC specimens, CDCP1 was overexpressed in 57% of samples, 38% of which exhibited a gain in CDCP1 copy number by fluorescence in situ hybridization (FISH). CDCP1 positivity was significantly associated between FISH and IHC. CDCP1 expression and gains in CDCP1 copy number synergized with nodal (N) status in determining disease-free and distant disease-free survival. The hazard ratios (HRs) of the synergies between CDCP1 positivity by IHC and FISH and lymph node positivity in predicting relapse did not differ significantly, indicating that CDCP1 overexpression in human primary TNBCs, regardless of being driven by gains in CDCP1, is for a critical factor in the progression of N-positive TNBCs. Thus, CDCP1 is a novel marker of the most aggressive N-positive TNBCs and a potential therapeutic target.

CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers / F. Turdo, F. Bianchi, P. Gasparini, M. Sandri, M. Sasso, L. De Cecco, L. Forte, P. Casalini, P. Aiello, L. Sfondrini, R. Agresti, M.L. Carcangiu, I. Plantamura, G. Sozzi, E. Tagliabue, M. Campiglio. - In: ONCOTARGET. - ISSN 1949-2553. - 7:43(2016 Oct 25), pp. 69649-69665. [10.18632/oncotarget.11935]

CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers

F. Bianchi
Co-primo
;
L. Sfondrini;
2016

Abstract

CDCP1, a transmembrane noncatalytic receptor, the expression of which has been associated with a poor prognosis in certain epithelial cancers, was found to be expressed in highly aggressive triple-negative breast cancer (TNBC) cell models, in which it promoted aggressive activities-ie, migration, invasion, anchorage-independent tumor growth, and the formation of vascular-like structures in vitro. By immunohistochemical (IHC) analysis of 100 human TNBC specimens, CDCP1 was overexpressed in 57% of samples, 38% of which exhibited a gain in CDCP1 copy number by fluorescence in situ hybridization (FISH). CDCP1 positivity was significantly associated between FISH and IHC. CDCP1 expression and gains in CDCP1 copy number synergized with nodal (N) status in determining disease-free and distant disease-free survival. The hazard ratios (HRs) of the synergies between CDCP1 positivity by IHC and FISH and lymph node positivity in predicting relapse did not differ significantly, indicating that CDCP1 overexpression in human primary TNBCs, regardless of being driven by gains in CDCP1, is for a critical factor in the progression of N-positive TNBCs. Thus, CDCP1 is a novel marker of the most aggressive N-positive TNBCs and a potential therapeutic target.
triple-negative breast cancer; CDCP1; CDCP1 copy number; prognosis; metastasis
Settore MED/04 - Patologia Generale
Settore MED/06 - Oncologia Medica
Settore BIO/17 - Istologia
Article (author)
File in questo prodotto:
File Dimensione Formato  
Oncotarget_2016.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 6.4 MB
Formato Adobe PDF
6.4 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/444752
Citazioni
  • ???jsp.display-item.citation.pmc??? 17
  • Scopus 23
  • ???jsp.display-item.citation.isi??? 23
social impact